Hepatitis A vaccines

References

• Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol. Rev.28, 101–111 (2006).
   PubMed Web of Science ®Google Scholar
• Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs63(23), 2625–2649 (2003).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Exp. Rev. Vaccines4(4), 459–471 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Hepatitis A. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (9th Edition). Atkinson W, Hamborsky J, McIntyre L, Wolfe S (Eds). Public Health Foundation, Washington, DC, USA 193–206 (2006).
   Google Scholar
• Centers for Disease Control (CDC). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.55(RR-7), 1–23 (2006).
   PubMedGoogle Scholar
• Berge JJ, Drennan DP, Jacobs RJ et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology31, 469–473 (2000).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis – United States, 2005. MMWR Morb. Mortal. Wkly Rep.56 (SS-3), 1–24 (2007).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K, Beutels P, Vaccines against hepatitis A. In: Textbook of Hepatology (Volume 1). Rodés J, Benhamou JP, Blei A, Reichen J, Rizzetto M (Eds). Blackwell Publishing, Oxford, UK 899–907 (2007).
   Google Scholar
• Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988–2004. Clin. Infect. Dis.42, 490–497 (2006).
   PubMed Web of Science ®Google Scholar
• Steffen R, Kane MA, Shapiro CN et al. Epidemiology and prevention of hepatitis A in travelers. JAMA272, 885–889 (1994).
   PubMed Web of Science ®Google Scholar
• Steffen R. Hepatitis A in travelers: the European experience. J. Infect. Dis.171(Suppl. 1), S24–S28 (1995).
   Google Scholar
• Lange WR, Frame JD. High incidence of viral hepatitis among American missionaries in Africa. Am. J. Trop. Med. Hyg.43, 527–533 (1990).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Feinstone SM, Bell BP. Hepatitis A vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, Inc., PA, USA 177–203 (2008).
   Google Scholar
• Northdurft HD, Dahlgren AL, Gallagher EA et al. The risk of acquiring hepatitis A and B among travelers in selected European and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination. J. Travel Med.14(3), 181–187 (2007).
   PubMedGoogle Scholar
• Mohler-Kuo M, Steffen R, Bopp M, Jacobs RJ, Mutsch M. Prevalence of hepatitis A virus risk factors in a very low endemic country, Switzerland. Vaccine25, 8718–8725 (2007).
   PubMedGoogle Scholar
• Viral Hepatitis and Prevention Board (VHPB). Prevention and control of hepatitis A in the United Kingdom. Viral Hepat.14(2), 13–14 (2006).
   Google Scholar
• Cotter SM, Sansom S, Lee B et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination. J. Infect. Dis.187, 1235–1240 (2003).
   PubMedGoogle Scholar
• Howitz MF, Mazick A, Cowan SA, Mølbak K. The economic impact of an epidemic of hepatitis A among men who have sex with men. Ugeskr. Laeg.169(41), 3489–3492 (2007).
   PubMedGoogle Scholar
• Mazick A, Howitz M, Rex S et al. Hepatitis A outbreak among MSM linked to casual sex and gay saunas in Copenhagen, Denmark. Euro Surveill.10(5), 111–114 (2005).
   PubMedGoogle Scholar
• Uhlmann S, Buxton JA. A provincial and territorial review of hepatitis A in men who have sex with men. Can. Commun. Dis. Rep.33(11), 1–11 (2007).
   PubMedGoogle Scholar
• Jin F, Prestage GP, Pell CM et al. Hepatitis A and B infection and vaccination in a cohort of homosexual men in Sydney. Sex. Health1(4), 227–237 (2004).
   PubMedGoogle Scholar
• Hutin YJ, Sabin KM, Hutwagner LC et al. Multiple modes of hepatitis A virus transmission among methamphetamine users. Am. J. Epidemiol.152(2), 186–192 (2000).
   PubMed Web of Science ®Google Scholar
• Spada E, Genovese D, Tosti ME et al. An outbreak of hepatitis A virus infection with a high case–fatality rate among injecting drug users. J. Hepatol.43(6), 958–964 (2005).
   PubMedGoogle Scholar
• Syed NA, Hearing SD, Shaw IS et al. Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur. J. Gastroenterol. Hepatol.15(8), 901–906 (2003).
   PubMedGoogle Scholar
• Tjon GM, Götz H, Koek AG et al. An outbreak of hepatitis A among homeless drug users in Rotterdam, The Netherlands. J. Med. Virol.77(3), 360–366 (2005).
   PubMedGoogle Scholar
• Fisher DG, Reynolds GL, Jaffe A, Perez MJ. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J. Addict. Dis.25(2), 25–32 (2006).
   PubMed Web of Science ®Google Scholar
• Hadler SC, Erben JJ, Francis DP, Webster HM, Maynard JE. Risk factors for hepatitis A in day-care centers. J. Infect. Dis.145(2), 255–261 (1982).
   PubMedGoogle Scholar
• Venczel LV, Desai MM, Vertz PD et al. The role of child care in a community-wide outbreak of hepatitis A. Pediatrics108(5), E78 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis A, Ruttimann RW, Jacobs RJ, Meyerhoff AS, Innis BL. Cost–effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev. Panam. Salud. Publica.21(6), 345–356 (2007).
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, Jacobs RJ, Artega O, Navarrete MS, Meyerhoff AS, Innis BL. Cost–effectiveness of universal hepatitis A vaccination in Chile. Vaccine23, 4110–4119 (2006).
   Google Scholar
• Vitral CL, Gaspar AM, Souto FJ. Epidemiological pattern and mortality rates for hepatitis A in Brazil, 1980–2002 – a review. Mem. Inst. Oswaldo Cruz101(2), 119–127 (2006).
   PubMed Web of Science ®Google Scholar
• Kunasol P, Cooksley G, Chan VF et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J. Trop. Med. Public Health29(2), 255–262 (1998).
   PubMedGoogle Scholar
• Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine18(Suppl. 1), S61–S64 (2008).
   Google Scholar
• Hadler SC, Erben JJ, Matthews D, Starko K, Francis DP, Maynard JE. Effect of immunoglobulin on hepatitis A in day-care centers. JAMA249(1), 48–53 (1983).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.55(RR-7), 9 (2006).
   Google Scholar
• Sonder GJB, van Steenbergen JE, Bovee J, Peerbooms PGH, Coutinho RA, van den Hoek A. Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996–2000: an evaluation of current prevention policy. Am. J. Public Health94, 1620–1626 (2004).
   PubMedGoogle Scholar
• Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J. Infect.49, 179–209 (2004).
   PubMed Web of Science ®Google Scholar
• Connor BA. Hepatitis A vaccine in the last-minute traveler. Am. J. Med.118(Suppl. 10A), 58S–62S (2005).
   PubMedGoogle Scholar
• Keystone JS, Hershey JH. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule. Int. J. Infect. Dis.12, 3–11 (2008).
   PubMedGoogle Scholar
• Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N. Engl. J. Med.357, 1685–1694 (2007).
   PubMed Web of Science ®Google Scholar
• Crowcroft NS. Protecting contacts of hepatitis A: what’s the difference between vaccine and human normal immunoglobulin? Epidemiol. Infect.136(1), 10–13 (2008).
   PubMedGoogle Scholar
• Kohl I, Nemecek V, Summerová M, Chlíbek R, Nad’ová K, Mináriková O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur. J. Epidemiol.21(12), 893–899 (2006).
   PubMedGoogle Scholar
• Petermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine10(Suppl. 1), S99–S101 (1992).
   Google Scholar
• Armstrong ME, Giesa PA, Davide JP et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J. Hepatol.18(Suppl. 2), S20–S26 (1993).
   PubMedGoogle Scholar
• Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years’ followup after the Monroe field trial of VAQTA. Vaccine20(13–14), 1699–1701 (2002).
   PubMed Web of Science ®Google Scholar
• Dagan R, Greenberg D, Goldenbertg-Gehtman P et al. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine17(15–16), 1919–1925 (1999).
   PubMed Web of Science ®Google Scholar
• Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine23(44), 5144–5148 (2005).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine15(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis A vaccine. Infection32(3), 149–152 (2004).
   PubMed Web of Science ®Google Scholar
• Mao JS. Development of live, attenuated hepatitis A vaccine (H2-strain). Vaccine8(6), 523–524 (1990).
   PubMed Web of Science ®Google Scholar
• Zhuang FC, Qian W, Mao ZA et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chin. Med. J.118(2), 1851–1856 (2005).
   PubMed Web of Science ®Google Scholar
• Minutello M, Zotti C, Orecchia S et al. Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster. Vaccine19(1), 10–15 (2000).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev. Vaccines3(3), 249–267 (2004).
   PubMedGoogle Scholar
• Beran J, Beutels M, Levie K et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J. Travel Med.8(5), 281 (2001).
   PubMedGoogle Scholar
• Overbosch D, Peyron F, Picot N et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J. Travel Med.12(6), 319–326 (2005).
   PubMed Web of Science ®Google Scholar
• Ford L, Beeching N. Improving practice – typhoid and combination vaccines. Drugs Context1(6), 313–396 (2005).
   Google Scholar
• World Health Organization (WHO). WHO position paper on hepatitis A vaccines. Wkly Epidemiol. Rec.75, 38–44 (2000).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.56(41), 1080–1084 (2007).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep.45(RR15), 1–30 (1996).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Prevention of Hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep.48(RR-12), 1–37 (1999).
   PubMedGoogle Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA294(2), 202–210 (2005).
   PubMed Web of Science ®Google Scholar
• Blaine Hollinger F, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. Hepatitis A and B vaccination and public health. J. Viral Hepat.14(Suppl. 1), 1–5 (2007).
   PubMedGoogle Scholar
• Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J. Infect. Dis.148, 1033–1039 (1983).
   PubMed Web of Science ®Google Scholar
• Bell BP, Negus S, Fiore A et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr. Infect. Dis. J.26, 116–122 (2007).
   PubMed Web of Science ®Google Scholar
• Connor BA, Van Herck, Van Damme P. Rapid protection and vaccination against hepatitis A for travelers. Biodrugs17(Suppl. 1), 19–21 (2003).
   PubMedGoogle Scholar
• Lee CY, Huang LM, Lee PI et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J. Trop. Med. Public Health31(1), 29–36 (2000).
   PubMedGoogle Scholar
• Castillo de Febres O, Chacon de Petrola M et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine18(7–8), 656–664 (1999).
   PubMed Web of Science ®Google Scholar
• Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine19(4–5), 399–402 (2000).
   PubMed Web of Science ®Google Scholar
• Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J. Travel Med.11, 120–121 (2004).
   PubMed Web of Science ®Google Scholar
• Williams JL, Bruden DA, Cagle HH et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine21(23), 3208–3211 (2003).
   PubMedGoogle Scholar
• Beck BR, Hatz C, Brönnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. CID37, 126–128 (2003).
   PubMed Web of Science ®Google Scholar
• Beck BR, Hatz CF, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J. Travel Med.11, 201–207 (2004).
   PubMed Web of Science ®Google Scholar
• Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules. J. Trop. Pediatr.49(6), 333–339 (2005).
   Google Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med. Infect. Dis.5, 79–84 (2007).
   PubMedGoogle Scholar
• Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J. Med. Virol.72, 194–196 (2004).
   PubMedGoogle Scholar
• Van Herck K, Renard D, Molenberghs G, Van Damme P. Model-based estimates of long-term persistence of vaccine induced hepatitis A antibodies. In: Viral Hepatitis and Liver Diseases. Proceedings of the Tenth International Symposium on Viral Hepatitis and Liver Diseases. 9–13 April 2000, Atlanta, USA. Margolis H, Alter M, Liang T, Dienstag J (Eds). International Medical Press, GA, USA 56–59 (2002).
   Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol.68, 489–493 (2002).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Beutels P, Van Damme P et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J. Med. Virol.60(1), 1–7 (2000).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Banatvala J, Fay O et al. Consensus statement: hepatitis A booster vaccination: is there a need ? Lancet362, 1065–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Cederna JB, Klinzmann D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine18, 892–898 (2000).
   Google Scholar
• Desombere I, Van Herck K, Van Damme P, Thoelen S, Collard F, Leroux-Roels G. Long-term persistence of cellular immunity towards hepatitis A vaccine (HAV) following HAV vaccination. Antiviral Ther.5(Suppl. 1), 7 (2000).
   PubMedGoogle Scholar
• Van Damme P, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? J. Travel Med.11, 179–181 (2004).
   PubMedGoogle Scholar
• Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA271, 1328–1334 (1994).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J.19, 1045–1052 (2000).
   PubMed Web of Science ®Google Scholar
• Letson GW, Shapiro CN, Kuehn D et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J. Pediatr.144, 327–332 (2004).
   PubMed Web of Science ®Google Scholar
• Troisi CL, Hollinger FB, Krause DS et al. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. Vaccine15, 1613–1617 (1997).
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasenas V, Valentelis R et al. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine21, 4588–4592 (2003).
   PubMed Web of Science ®Google Scholar
• Lagos R, Munoz A, Dumas R et al. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in the presence of maternal antibodies. Vaccine21, 3730–3733 (2003).
   PubMed Web of Science ®Google Scholar
• Kemper CA, Haubrick R, Frank I et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J. Infect. Dis.187, 1327–1331 (2003).
   PubMed Web of Science ®Google Scholar
• Wallace MR, Brandt CJ, Earhart KC et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected patients. Clin. Infect. Dis.39, 1207–1213 (2004).
   PubMed Web of Science ®Google Scholar
• Gouvea AFTB, De Moraes-Pinto MI, Ono E et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin. Infect. Dis.41, 544–548 (2005).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology27, 881–886 (1998).
   PubMedGoogle Scholar
• Lee SD, Chan CY, Yu MY. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J. Med. Virol.52, 215–218 (1997).
   PubMedGoogle Scholar
• McMahon BJ, Williams J, Bulkow L et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J. Infect. Dis.171, 676–679 (1995).
   PubMedGoogle Scholar
• Reuman PD, Kubilis P, Hurni et al. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine15, 1157–1161 (1997).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Hepatitis A outbreak associated with green onions at a restaurant – Monaca, Pennsylvania, 2003. MMWR Morb. Mortal. Wkly Rep.52, 1155–1157 (2003).
   PubMedGoogle Scholar